Numerous developments are enabling ever more personalised leukemia treatments with lower toxicity Published on 19/06/2023 Recent studies have sought to demonstrate the effectiveness of new targeted therapies, such as FLT3 or menin inhibitors, and cellular therapy such as CAR-T in ever earlier scenarios
Research into acute leukemia moves towards "tailor-made" treatments for each individual patient Published on 22/11/2022 Research into acute leukemia is currently one of the most active fields in Spain due to the shortcomings persisting in the treatment of these patients, who amount to more than 6,000 every year1
Hematologists face the challenge of incorporating Target Therapies into daily practice in the treatment of acute leukemia Published on 10/11/2021 Better understanding of cell tumor biology opens possibilities for targeted therapies in acute leukemia
Systemic mastocytosis, a disease of rare diagnosis, to be studied at the 10th Acute Leukemia Conference of MD Anderson Madrid Published on 27/09/2021 It will feature prominent speakers from different countries in America and Europe, as well as the intervention of professionals from the MD Anderson leukemia department in Houston
IDH inhibitors give very positive results in relapsed acute myeloblastic leukemia patients with the mutation Published on 08/10/2019 Acting on this therapy target would give favorable results in both monotherapy and in combination with other agents, thus improving life expectancy of patients with acute myeloblastic leukemia (AML)